4 recruiting, 3 completed, 2 terminated, 1 active not recruiting. 3 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 3 | 3 | Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow Familial dermographism: new trials by email Literature Review of Familial dermographism trials Research Report on Familial dermographism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD) Barzolvolimab, Matching Placebo - Chronic Inducible Urticaria, Cold Urticaria | Phase 3 | Recruiting | Celldex Therapeutics | 240 | 2026-01-15 | 2026-10-07 |
| A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria GTX-B001, Normal Saline - Healthy Subjects, Cold Urticaria | Phase 1 | Recruiting | Granular Therapeutics Limited | 72 | 2025-10-06 | 2026-09-09 |
| Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) BLU-808, Placebo - Chronic Inducible Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Active not recruiting | Blueprint Medicines Corporation | 105 | 2025-05-28 | 2026-07-22 |
| Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria Remibrutinib, Placebo - Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU) | Phase 2 | Recruiting | Novartis Pharmaceuticals | 44 | 2025-05-22 | 2026-09-28 |
| Deep Phenotyping of CIndU Skin Diseases, Angio-Oedema and/or Urticaria | Recruiting | Centre for Human Drug Research, Netherlands | 40 | 2025-01-21 | 2026-01-22 | |
| Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines Ligelizumab, Placebo - Chronic Inducible Urticaria | Phase 3 | Terminated | Novartis Pharmaceuticals | 39 | 2021-11-16 | 2024-06-18 |
| A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria CDX-0159 - Cold Urticaria, Cold Contact Urticaria | Phase 1 | Completed | Celldex Therapeutics | 41 | 2020-11-24 | 2023-05-17 |
| Antihistamines in the Treatment of Irritable Bowel Syndrome With Diarrhea Antihistamine, Placebo - Irritable Bowel Syndrome, Dermatographism | Phase 3 | Withdrawn | University of Cincinnati | 2020-02-01 | 2026-09-04 | |
| Urticaria Facticia Treatment With Omalizumab (UFO) Omalizumab, Placebo - Symptomatic Dermographism | Phase 2 | Completed | Charite University, Berlin, Germany | 61 | 2012-12-01 | 2020-11-03 |
| Pathogenesis of Physical Induced Urticarial Syndromes Hypersensitivity, Immediate, Autoinflammatory Syndromes | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 173 | 2009-06-17 | 2026-03-30 | |
| The Effect of Levocetirizine on Inflammatory Mediators in Dermatographism levocetirizine or placebo - Rhinitis, Urticaria | Terminated | Wake Forest University | 11 | 2009-04-01 | 2017-02-28 |
Chronic Inducible Urticaria (6) · Cold Urticaria (6) · Urticaria (4) · Chronic Urticaria (3) · Skin Diseases (2) · Cryopyrin-Associated Periodic Syndromes (1) · Hypersensitivity, Immediate (1) · Irritable Bowel Syndrome (1) · Pruritus (1) · Rhinitis (1) · Urticaria, Solar (1)
Hypersensitivity (9) · Immune System Diseases (9) · Skin Diseases, Vascular (9) · Skin and Connective Tissue Diseases (9) · Chronic Disease (8) · Disease Attributes (8) · Hypersensitivity, Immediate (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Skin Diseases (7) · Chronic Urticaria (5) · Urticaria (5) · Chronic Inducible Urticaria (1) · Cold Urticaria (1) · Colonic Diseases (1)
Cetirizine (1) · Famotidine (1) · Histamine Antagonists (1) · Omalizumab (1) · Saline Solution (1) · levocetirizine (1) · ligelizumab (1) · remibrutinib (1)
Celldex Therapeutics (2) · Novartis Pharmaceuticals (2) · Blueprint Medicines Corporation (1) · Centre for Human Drug Research, Netherlands (1) · Charite University, Berlin, Germany (1) · Granular Therapeutics Limited (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University of Cincinnati (1) · Wake Forest University (1)
United States (7) · Germany (6) · Spain (4) · Poland (2) · Taiwan (2) · Australia (1) · Denmark (1) · France (1) · Greece (1) · Hungary (1) · Italy (1) · Lithuania (1) · Netherlands (1) · Russia (1) · Slovakia (1)
David Bernstein, MD (1) · Gil Yosipovitch, MD (1) · Hirsh D Komarow, M.D. (1) · Martin Metz, MD (1)
2025 (1)